Harvard Bioscience Posts Strong Q4, Eyes Translational Science Growth
Event summary
- Harvard Bioscience reported preliminary Q4 2025 revenue of $23.7M, exceeding guidance midpoint.
- Gross margin hit 60%, at the high end of the 58-60% range, driven by cost reductions and higher-margin products.
- Adjusted EBITDA grew 27% year-over-year to $3.8M, with management forecasting mid-to-high single-digit EBITDA growth for 2026.
- Company outlines four strategic pillars: translational science leadership, new product pipeline, consumables expansion, and operational excellence.
- Full Q4 and 2025 results to be released March 12, 2026.
The big picture
Harvard Bioscience is positioning itself as a leader in translational science tools, aligning with the industry's shift toward New Approach Methodologies (NAMs). The company's strategic focus on high-margin consumables and operational efficiency reflects broader trends in life sciences toward sustainable growth and cost optimization. With a strong Q4 performance and positive 2026 outlook, Harvard Bioscience aims to leverage its preclinical foundation to bridge the gap between laboratory research and clinical success.
What we're watching
- Translational Science Shift
- How Harvard Bioscience's pivot to translational science will position it in the growing NAMs market.
- Consumables Expansion
- Whether the focus on higher-margin consumables can sustain recurring revenue growth.
- Operational Execution
- The pace at which cost discipline and manufacturing consolidation will improve profitability.
Related topics